By Dr John Walter Frew

Journal articles

Navrazhina K; Frew JW; Gilleaudeau P; Sullivan-Whalen M; Garcet S; Krueger JG, 2021, 'Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa', Journal of Allergy and Clinical Immunology, 147, pp. 2213 - 2224, http://dx.doi.org/10.1016/j.jaci.2020.12.651

Zouboulis CC; Frew JW; Giamarellos-Bourboulis EJ; Jemec GBE; del Marmol V; Marzano AV; Nikolakis G; Sayed CJ; Tzellos T; Wolk K; Prens EP, 2021, 'Target molecules for future hidradenitis suppurativa treatment', Experimental Dermatology, 30, pp. 8 - 17, http://dx.doi.org/10.1111/exd.14338

Grand D; Frew JW; Navrazhina K; Krueger JG, 2021, 'Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity', British Journal of Dermatology, 184, pp. 688 - 696, http://dx.doi.org/10.1111/bjd.19343

Frew JW; Lowes MA; Goldfarb N; Butt M; Piguet V; O'Brien E; Ingram J; Jemec GBE; Tan J; Zouboulis C; Alavi A; Kirby JS, 2021, 'Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary', JAMA Dermatology, 157, pp. 449 - 455, http://dx.doi.org/10.1001/jamadermatol.2020.5467

Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG, 2021, 'Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab', Clinical and Experimental Dermatology, 46, pp. 306 - 313, http://dx.doi.org/10.1111/ced.14448

Frew J; Penzi L; Suarez-Farinas M; Garcet S; Brunner PM; Czarnowicki T; Kim J; Bottomley C; Finney R; Cueto I; Fuentes-Duculan J; Ohmatsu H; Lentini T; Yanofsky V; Krueger JG; Guttman-Yassky E; Gareau D, 2021, 'The erythema Q-score, an imaging biomarker for redness in skin inflammation', Experimental Dermatology, 30, pp. 377 - 383, http://dx.doi.org/10.1111/exd.14224

Frew JW; Marzano AV; Wolk K; Join-Lambert O; Alavi A; Lowes MA; Piguet V, 2021, 'A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance', Journal of Investigative Dermatology, 141, pp. 316 - 324.e2, http://dx.doi.org/10.1016/j.jid.2020.06.019

van Straalen KR; Frew JW, 2021, 'The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa', Journal of Investigative Dermatology, 141, pp. 429 - 431, http://dx.doi.org/10.1016/j.jid.2020.03.977

Frew JW; Navrazhina K; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Krueger JG, 2021, 'Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study', British Journal of Dermatology, 184, pp. 350 - 352, http://dx.doi.org/10.1111/bjd.19478

Frew JW; Krueger JG, 2021, 'What's in the pipeline for hidradenitis suppurativa? Emerging and novel therapeutics', Drugs of the Future, 46, pp. 43 - 60, http://dx.doi.org/10.1358/DOF.2021.46.1.3220744

Williams S; Navrazhina K; Frew J; Garcet S; Krueger JG, 2021, '700 Vascularization in the deep dermis of hidradenitis suppurativa lesions', Journal of Investigative Dermatology, 141, pp. S121 - S121, http://dx.doi.org/10.1016/j.jid.2021.02.730

Navrazhina K; Renert-Yuval Y; Frew J; Grand D; Garcet S; Krueger JG, 2021, '703 Blood analysis uncovers novel inflammatory, oncologic and cardiovascular biomarkers in psoriasis and Hidradenitis Suppurativa', Journal of Investigative Dermatology, 141, pp. S122 - S122, http://dx.doi.org/10.1016/j.jid.2021.02.733

Frew J; Penzi L; Suarez‐Farinas M; Garcet S; Brunner PM; Czarnowicki T; Kim J; Bottomley C; Finney R; Cueto I; Fuentes‐Duculan J; Ohmatsu H; Lentini T; Yanofsky V; Krueger JG; Guttman‐Yassky E; Gareau D, 2021, 'Cover Image', Experimental Dermatology, 30, http://dx.doi.org/10.1111/exd.14328

Frew JW; Jiang CS; Singh N; Navrazhina K; Vaughan R; Krueger JG, 2020, 'Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial design', JAAD International, 1, pp. 208 - 221, http://dx.doi.org/10.1016/j.jdin.2020.09.005

Zouboulis CC; Benhadou F; Byrd AS; Chandran NS; Giamarellos-Bourboulis EJ; Fabbrocini G; Frew JW; Fujita H; González-López MA; Guillem P; Gulliver WPF; Hamzavi I; Hayran Y; Hórvath B; Hüe S; Hunger RE; Ingram JR; Jemec GBE; Ju Q; Kimball AB; Kirby JS; Konstantinou MP; Lowes MA; MacLeod AS; Martorell A; Marzano AV; Matusiak Ł; Nassif A; Nikiphorou E; Nikolakis G; Nogueira da Costa A; Okun MM; Orenstein LAV; Pascual JC; Paus R; Perin B; Prens EP; Röhn TA; Szegedi A; Szepietowski JC; Tzellos T; Wang B; van der Zee HH, 2020, 'What causes hidradenitis suppurativa ?—15 years after', Experimental Dermatology, 29, pp. 1154 - 1170, http://dx.doi.org/10.1111/exd.14214

Tee MW; Avarbock AB; Ungar J; Frew JW, 2020, 'Rapid resolution of pyoderma gangrenosum with brodalumab therapy', JAAD Case Reports, 6, pp. 1167 - 1169, http://dx.doi.org/10.1016/j.jdcr.2020.08.033

Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG, 2020, 'The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study', Journal of the American Academy of Dermatology, 83, pp. 1341 - 1348, http://dx.doi.org/10.1016/j.jaad.2020.05.007

Garcia-Doval I; Segovia E; Hunter H; Frew J; Naldi L, 2020, 'The value of case reports in pharmacovigilance', British Journal of Dermatology, 183, pp. 795 - 796, http://dx.doi.org/10.1111/bjd.19504

Naik HB; Alhusayen R; Frew J; Guilbault S; Ingram JR; Lowes MA; Marzano AV; Paul M; Villumsen B; Yannuzzi CA, 2020, 'Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices', British Journal of Dermatology, 183, pp. 780 - 781, http://dx.doi.org/10.1111/bjd.19345

Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG, 2020, 'Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa', Clinical and Experimental Dermatology, 45, pp. 859 - 865, http://dx.doi.org/10.1111/ced.14264

Frew JW, 2020, 'Anti–Saccharomyces cervisiae antibodies in hidradenitis suppurativa: More than a gut feeling', Journal of Allergy and Clinical Immunology, 146, pp. 458, http://dx.doi.org/10.1016/j.jaci.2020.03.022

Frew JW, 2020, 'Primary imputation methods impact efficacy results in hidradenitis suppurativa clinical trials', Journal of the American Academy of Dermatology, 83, pp. 663 - 665, http://dx.doi.org/10.1016/j.jaad.2020.03.078

Kamil MAA; Chandran NS; Sulistyaningrum SK; Rajagopalan M; Tahiliani S; Hsiao J; Naik H; Shi V; Frew JW, 2020, 'The Asia Pacific Hidradenitis Suppurativa (APHiS) foundation: promoting hidradenitis suppurativa research in the Asia Pacific', International Journal of Dermatology, 59, pp. e289 - e290, http://dx.doi.org/10.1111/ijd.14960

Frew JW; Piguet V, 2020, 'Ex Vivo Models and Interpretation of Mechanistic Studies in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 140, pp. 1323 - 1326, http://dx.doi.org/10.1016/j.jid.2020.02.014

Frew JW, 2020, 'Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence', JAAD International, 1, pp. 62 - 72, http://dx.doi.org/10.1016/j.jdin.2020.05.005

Frew JW, 2020, 'The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity?', Journal of Dermatological Treatment, 31, pp. 422 - 423, http://dx.doi.org/10.1080/09546634.2019.1601668

Frew JW; Grand D; Navrazhina K; Krueger JG, 2020, 'Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets?', Experimental Dermatology, 29, pp. 509 - 515, http://dx.doi.org/10.1111/exd.14092

Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG, 2020, 'Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data', Journal of the American Academy of Dermatology, 82, pp. 1150 - 1157, http://dx.doi.org/10.1016/j.jaad.2019.12.044

Price KN; Frew JW; Hsiao JL; Shi VY, 2020, 'COVID-19 and immunomodulator/immunosuppressant use in dermatology', Journal of the American Academy of Dermatology, 82, pp. e173 - e175, http://dx.doi.org/10.1016/j.jaad.2020.03.046

Navrazhina K; Frew JW; Krueger JG, 2020, 'Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa', British Journal of Dermatology, 182, pp. 1045 - 1047, http://dx.doi.org/10.1111/bjd.18556

Frew JW; Navrazhina K, 2020, 'No evidence that impaired Notch signalling differentiates hidradenitis suppurativa from other inflammatory skin diseases', British Journal of Dermatology, 182, pp. 1042 - 1043, http://dx.doi.org/10.1111/bjd.18593

Frew JW, 2020, 'Putting nodule counts behind us: hidradenitis suppurativa outcome measures independent of descriptive semantics', British Journal of Dermatology, 182, pp. 829 - 830, http://dx.doi.org/10.1111/bjd.18436

Phan K; Tatian A; Woods J; Cains G; Frew JW, 2020, 'Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis', International Journal of Dermatology, 59, pp. 221 - 228, http://dx.doi.org/10.1111/ijd.14697

Navrazhina K; Frew JW, 2020, 'Consensus definitions of disease activity in hidradenitis suppurativa: crossing the semantic gap', British Journal of Dermatology, 182, pp. 7, http://dx.doi.org/10.1111/bjd.18468

Grand D; Navrazhina K; Frew JW, 2020, 'Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa', Experimental Dermatology, 29, pp. 86 - 92, http://dx.doi.org/10.1111/exd.14056

Garcet S; Frew JW; Navrazhina K; Krueger J, 2020, '062 Hidradenitis suppurativa RNA-seq skin transcriptome overlaps with psoriasis vulgaris and reveals a marked upregulation of multiple targetable cytokines', Journal of Investigative Dermatology, 140, pp. S7 - S7, http://dx.doi.org/10.1016/j.jid.2020.03.064

Navrazhina K; Frew JW; Grand D; Sullivan-Whalen MM; Gilleaudeau P; Krueger JG, 2020, '14928 Epithelialized tracts are active mediators of inflammation in hidradenitis suppurativa', Journal of the American Academy of Dermatology, 83, pp. AB24 - AB24, http://dx.doi.org/10.1016/j.jaad.2020.06.184

Grand D; Frew JW; Navrazhina K; Krueger J, 2020, '520 Establishing the analytical and clinical validity of sonographic biomarkers in hidradenitis suppurativa', Journal of Investigative Dermatology, 140, pp. S71 - S71, http://dx.doi.org/10.1016/j.jid.2020.03.529

Navrazhina K; Frew JW; Gulati N; Grand D; Garcet S; Mitsui H; Krueger JG, 2020, '703 Laser Capture Microdissection and genetic analysis identify dysplastic nevi as a subgroup of common nevi rather than a progressive state towards melanoma', Journal of Investigative Dermatology, 140, pp. S94 - S94, http://dx.doi.org/10.1016/j.jid.2020.03.715

Frew JW; Navrazhina K; Garcet S; Krueger J, 2020, '880 Targeted IL-17RA antagonism ameliorates histological and transcriptomic features of hidradenitis suppurativa: A proof of concept study', Journal of Investigative Dermatology, 140, pp. S115 - S115, http://dx.doi.org/10.1016/j.jid.2020.03.896

Frew JW; Navrazhina K; Byrd AS; Garg A; Ingram JR; Kirby JS; Lowes MA; Naik H; Piguet V; Prens EP, 2019, 'Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies', British Journal of Dermatology, 181, pp. 1339 - 1341, http://dx.doi.org/10.1111/bjd.18309

Frew J; Wu X; Hsiung GY; Feldman HH; Mackenzie IR; Nygaard HB, 2019, 'Generation of an induced pluripotent stem cell line (UBCi001-A) from a presymptomatic individual carrying the R418X progranulin gene mutation', STEM CELL RESEARCH, 41, http://dx.doi.org/10.1016/j.scr.2019.101582

Frew JW; Navrazhina K, 2019, 'Into the (gluteal) fold: pilonidal disease and hidradenitis suppurativa – association or continuum?', British Journal of Dermatology, 181, pp. 1121, http://dx.doi.org/10.1111/bjd.18300

Byrd AS; Dina Y; Okoh UJ; Quartey QQ; Carmona-Rivera C; Williams DW; Kerns ML; Miller RJ; Petukhova L; Naik HB; Barnes LA; Shipman WD; Caffrey JA; Sacks JM; Milner SM; Aliu O; Broderick KP; Kim D; Liu H; Dillen CA; Ahn R; Frew JW; Kaplan MJ; Kang S; Garza LA; Miller LS; Alavi A; Lowes MA; Okoye GA, 2019, 'Specimen Collection for Translational Studies in Hidradenitis Suppurativa', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-019-48226-w

Grand D; Navrazhina K; Frew JW, 2019, 'A Scoping Review of Non-invasive Imaging Modalities in Dermatological Disease: Potential Novel Biomarkers in Hidradenitis Suppurativa', Frontiers in Medicine, 6, pp. 253, http://dx.doi.org/10.3389/fmed.2019.00253

FREW J; MURRELL DF, 2019, 'Improving clinical applications of quality of life scores in epidermolysis bullosa: defining clinically significant outcomes in the QOLEB questionnaire', Mucosa, 2, pp. 68 - 75, http://dx.doi.org/10.33204/mucosa.598339

Frew JW; Navrazhina K, 2019, 'In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations', Frontiers in Medicine, 6, http://dx.doi.org/10.3389/fmed.2019.00206

Frew JW; Hawkes JE; Sullivan-Whalen M; Gilleaudeau P; Krueger JG, 2019, 'Inter-rater reliability of phenotypes and exploratory genotype–phenotype analysis in inherited hidradenitis suppurativa', British Journal of Dermatology, 181, pp. 566 - 571, http://dx.doi.org/10.1111/bjd.17695

Tatiane A; Slape D; Lawless R; Frew JW, 2019, 'A systematic review of reported cases of pachyonychia congenita tarda', Clinical and Experimental Dermatology, 44, pp. 606 - 612, http://dx.doi.org/10.1111/ced.13980

Frew JW, 2019, 'Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease', Journal of the European Academy of Dermatology and Venereology, 33, pp. e298 - e300, http://dx.doi.org/10.1111/jdv.15572

Back to profile page